Bayer
Evotec and Bayer announce new kidney disease study
December 11, 2025Research and Development Bayer, Evotec, Nephrology
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney disease, stemming from their previous …
Third application for Orion’s prostate cancer drug submitted by partner Bayer
September 23, 2024Bayer, Cancer, Oncology, orion, prostate cancer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, …
Bayer and Evotec to collaborate on precision cardiology
April 30, 2024Research and Development Bayer, Cardiology, cardio, cvd
Bayer and Evotec have announced that they have updated the focus of their collaboration to work on the development of …
Bayer and Aignostics to collaborate for AI oncology research
March 14, 2024Research and Development AI, Bayer, Oncology, research
Bayer and Aignostics have announced that they have entered into a strategic collaboration for several artificial intelligence (AI)-powered approaches for …
Bayer’s cardiovascular drug shows impressive Phase III results
May 11, 2021Manufacturing and Production Bayer, chronic kidney disease, pharma, pharma news, type 2 diabetes
Bayer’s finerenone drug has been shown to significantly reduce cardiovascular death or other cardiovascular events in patients with chronic kidney …
Bayer’s venous thromboembolism drug Xarelto gets UK approval for children
February 1, 2021Sales and Marketing Bayer
Bayer has received UK approval for the use of its oral Factor Xa inhibitor Xarelto (rivaroxaban) to treat venous thromboembolism …
Bayer and CureVac to collaborate on COVID-19 vaccine candidate
January 8, 2021Medical Communications Bayer, COVID-19, Vaccine
Bayer is joining forces with CureVac, a biopharmaceutical company developing medicines based on messenger ribonucleic acid (mRNA), on its COVID-19 …
Bayer buys out US-based Asklepios BioPharmaceutical in potential $4bn deal
October 26, 2020Sales and Marketing Asklepios, Bayer, acquisition, pharma
Bayer has moved to bolster its cell and gene therapy (CGT) business through the acquisition of US biotech Asklepios BioPharmaceutical …
Bayer’s Nubeqa secures NICE recommendation for hormone-relapsed prostate cancer at risk of metastasis
October 23, 2020Medical Communications, Sales and Marketing Bayer, NCIE, Nubeqa, pharma
NICE has given its recommendation to Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for …
Bayer scoops up women’s healthcare biotech KaNDy Therapeutics in potential $1bn+ deal
August 11, 2020Manufacturing and Production, Research and Development, Sales and Marketing Bayer, KaNDy Therapeutics, menopause, pharma
Bayer is set to acquire UK-based biotech KaNDy Therapeutics, assimilating the firm’s women’s healthcare development portfolio in a newly announced …
FDA grants fast review for Bayer and MSD’s heart failure drug vericiguat
July 17, 2020Medical Communications Bayer, FDA, MSD
The FDA has granted a fast Priority Review for Bayer and MSD’s heart failure drug vericiguat. This was based on …
Bayer’s Vitrakvi becomes first tumour-agnostic therapy approved by NICE for NHS patients with NTRK fusion+ cancer
April 21, 2020Manufacturing and Production, Sales and Marketing Bayer, Cancer, NICE, UK, Vitrakvi, tumour agnostic
Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) has just been recommended by NICE in the treatment of advanced neurotrophic tyrosine receptor …
Bayer’s Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer
March 31, 2020Manufacturing and Production, Research and Development Bayer, Cancer, Europe, Nubeqa, prostate cancer
The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, …
GW Pharma takes back control of UK Sativex sales from Bayer
March 2, 2020Sales and Marketing Bayer, GW Pharma, Sativex, UK
British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis …
Bayer’s Eylea shows strong vision benefits across two regimens in post-marketing study
February 5, 2020Research and Development Bayer, Eylea, pharma
Bayer has pulled back the curtain on new Phase 4 data for Eylea (aflibercept), revealing strong findings in the treatment …
Latest content
